[Evaluation of therapeutic inertia in lipid lowering treatment of primary care patients with high cardiovascular risk].
作者信息
de Pablos Vicente Maria Asunción, Leal Hernández Mariano, Balanza Galindo Serafín, Abellán Alemán José
出版信息
Aten Primaria. 2012 Mar;44(3):e14-5. doi: 10.1016/j.aprim.2011.02.011. Epub 2011 Jul 2.
Abstract
摘要
相似文献
1
[Evaluation of therapeutic inertia in lipid lowering treatment of primary care patients with high cardiovascular risk].
Aten Primaria. 2012 Mar;44(3):e14-5. doi: 10.1016/j.aprim.2011.02.011. Epub 2011 Jul 2.
2
Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.
PLoS One. 2013 Jul 26;8(7):e67611. doi: 10.1371/journal.pone.0067611. Print 2013.
3
Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION-Denmark trial.
Diabet Med. 2014 Dec;31(12):1577-85. doi: 10.1111/dme.12574. Epub 2014 Sep 29.
4
Countering clinical inertia in lipid management: Expert workshop summary.
Am Heart J. 2018 Dec;206:24-29. doi: 10.1016/j.ahj.2018.09.003. Epub 2018 Sep 14.
5
Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.
Circulation. 2001 Jan 2;103(1):38-44. doi: 10.1161/01.cir.103.1.38.
6
Co-prescription patterns of cardiovascular preventive treatments: a cross-sectional study in the Aragon worker' health study (Spain).
BMJ Open. 2019 Apr 14;9(4):e023571. doi: 10.1136/bmjopen-2018-023571.
7
Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.
Cardiovasc Diabetol. 2011 Apr 17;10:31. doi: 10.1186/1475-2840-10-31.
8
Three years follow-up of screen-detected diabetic and non-diabetic subjects: who is better off? The ADDITION Netherlands study.
BMC Fam Pract. 2008 Dec 16;9:67. doi: 10.1186/1471-2296-9-67.
9
Niacin: another look at an underutilized lipid-lowering medication.
Nat Rev Endocrinol. 2012 Sep;8(9):517-28. doi: 10.1038/nrendo.2012.22. Epub 2012 Feb 21.
10
Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
Scand J Prim Health Care. 2015;33(4):260-8. doi: 10.3109/02813432.2015.1117281.
引用本文的文献
1
[Trends in the level of control of patients with type 2 diabetes from 2010 to 2015].
Aten Primaria. 2018 Oct;50(8):459-466. doi: 10.1016/j.aprim.2017.04.002. Epub 2017 Aug 21.
本文引用的文献
1
Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin.
Ann Fam Med. 2007 May-Jun;5(3):196-201. doi: 10.1370/afm.679.
2
Systematic review: the relationship between clinical experience and quality of health care.
Ann Intern Med. 2005 Feb 15;142(4):260-73. doi: 10.7326/0003-4819-142-4-200502150-00008.
3
Clinical inertia.
Ann Intern Med. 2001 Nov 6;135(9):825-34. doi: 10.7326/0003-4819-135-9-200111060-00012.
Zotero 插件